Study of CRx-191 to Assess Activity in Plaque Psoriasis
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
CRx-191 is a proprietary synergistic combination drug candidate being evaluated by
CombinatoRx for topical psoriasis therapy. CRx-191 was identified via a proprietary screening
assay for novel drug combinations demonstrating enhanced inhibition of tumor necrosis factor-
alpha and interferon-gamma release, cytokines that are implicated in the pathogenesis of
psoriasis.
This clinical trial will assess the effectiveness of CRx-191 in reducing the psoriatic
infiltrate band thickness as measured by transdermal ultrasound. All subjects will receive
all treatments in separate test fields, with intra-individual comparison of the treatments.